Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors (ICOnnectat-B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04372459
Recruitment Status : Not yet recruiting
First Posted : May 4, 2020
Last Update Posted : November 27, 2020
Sponsor:
Information provided by (Responsible Party):
Cristian Ochoa Arnedo, Institut Català d'Oncologia

Brief Summary:
This multicenter randomized controlled study will appraise the effectiveness and cost-utility of an e-health ecosystem with integrated and stepped psychosocial services that will be compared with the usual psychosocial care. The study is developed in the acute survival phase among breast cancer survivors. The outcomes of both interventions will be compared in terms of the amount of waiting time to receive psychosocial care and changes in several psychosocial variables. Finally, a comparative economic analysis will be conducted in other relevant psychosocial and health parameters. The e-health platform is expected to outperform usual care in the aforementioned indicators, while reaching high acceptability and usability by survivors, and additionally reducing costs for health providers.

Condition or disease Intervention/treatment Phase
Breast Cancer Psychological Distress Emotional Disorder Behavioral: Online integrated and stepped psychosocial care Behavioral: Usual psychosocial care Not Applicable

Detailed Description:

Cancer diagnosis and treatment causes a huge psychosocial impact on breast cancer survivors. Psychosocial treatments in cancer survivors have already demonstrated their effectiveness in reducing emotional distress and improving quality of life although the access to them still presents important barriers, such as poor early detection, long waiting times for diagnosis or treatment, as well as other restrictions related to work, mobility or economic situation. In addition, the current digitization of screening, monitoring and psychosocial treatment poses a revolution in the improvement of the quality of care and the reduction of its economic burden. The objectives of this study are, first, to assess the clinical efficacy of an e-health platform that includes integrated and stepped psychosocial services, in comparison to usual psychosocial care, and second, to examine its cost-utility.

The study methodology is that of a multicentre randomised controlled trial with 2 parallel groups (experimental versus control group). Approximately 193 patients diagnosed with breast cancer in the acute survival phase will be recruited from 3 University hospitals in Catalonia (Spain) and will be randomised to one of two treatment conditions. All participants will be evaluated at the beginning of the study (T1: recruitment), 3 months from T1 (T2), 6 months from T1 (T3) and 12 months from T1 (T4). Primary outcome measures will include detection of clinical cases, amount of waiting time from detection to psychosocial intervention, and proportion of cases solved in the different steps of the intervention, as well as outcomes related to emotional distress, quality of life, post-traumatic stress and growth and therapeutic alliance. Secondary outcomes will include the acceptability of the platform by patients through satisfaction questionnaires and the usability of the platform. For the cost-utility analysis, the investigators will assess quality-adjusted life years (QALYs) and costs related to the number of days of sick leaves, healthcare utilization, adherence to pharmacological treatment, health professionals' costs, infrastructure and transport costs.

The study will provide an important advance in the treatment of breast cancer; in the long term, it is expected to improve the quality of patient care and the treatment efficacy and to reduce waiting lists as well as direct and indirect costs associated with the treatment of the disease in Spain.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 193 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The current clinical trial is a multicenter Randomised Controlled Trial with 2 parallel groups. The effectiveness of the online integrated and stepped psychosocial care group will be compared with the usual psychosocial care group
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Online Psychosocial Cancer Screening, Monitoring and Stepped Treatment in Cancer Survivors: A Randomized Controlled Trial
Estimated Study Start Date : January 1, 2021
Estimated Primary Completion Date : June 30, 2022
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Online integrated and stepped psychosocial care
A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the online integrated and stepped psychosocial care group
Behavioral: Online integrated and stepped psychosocial care

This program features four levels of care, increasing in intensity of psychosocial care as patients move from one level to the next one.

Step 1: Screening and monitoring of several psychosocial variables through the central mobile application of the program (App ICOnnecta't).

Step 2: Online guided and self-help psychoeducation Campus in which patients can consult videos and online resources, co-constructed between health professionals and patients, containing reliable and rigorous information related to the oncological process.

Step 3: Online community of psychosocial support. Participants can choose from 12 cancer-related discussion forums and share with the community any health-related question that worries them fostering, thus, debate and stimulating peer-support.

Step 4: Intensive online group psychotherapy (App ICOnnecta't Videoconsultation), based on the Group Positive Psychotherapy program for cancer survivors (Ochoa, Sumalla, Maté, Castejón, Rodríguez et al., 2010).


Experimental: Usual psychosocial care
A group of breast cancer survivors will be randomly allocated (1:1 allocation) to the usual psychosocial care group
Behavioral: Usual psychosocial care
This active control group will receive the standard psychosocial treatment for cancer survivors in the participating centers, led by a clinical psychologist and consisting of 8 individual, 45/60-minute sessions, each of which every 1-2 months, focused on providing emotional support and psychoeducation during the first year of primary cancer treatment.




Primary Outcome Measures :
  1. Change in Emotional Distress (HADS) [ Time Frame: Time 1: Baseline; Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983; Spanish validation by Costa-Requena, Pérez Martín, Salamero Baró, & Gil Moncayo, 2009). It consists of 14 items, 7 for anxiety and 7 for depression, on a four-point Likert scale (range 0-3), with the total score ranging from 0 to 42. Higher scores indicate a greater level of distress.

  2. Change in Post-traumatic Stress (PCL-5) [ Time Frame: Time 1: Baseline; Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    Post-traumatic Stress Disorder Checklist-Civilian version (PCL-5) (Blevins, Weathers, Davis, Witte, & Domino, 2015). The official Spanish translation of the instrument was provided by the National Center for Post-Traumatic Stress Disorder (www.ptsd.va.gov/). The PCL-5 is a 20-item questionnaire, corresponding to the "Diagnostic and Statistical Manual for Mental Disorders Version 5" symptom criteria for PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version. Rating scale descriptors are the same: "Not at all," "A little bit," Moderately," "Quite a bit," and "Extremely." A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items, with higher scores indicating worse outcomes.

  3. Change in Post-traumatic Growth (PTGI) [ Time Frame: Time 1: Baseline; Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    Post-traumatic Growth Inventory (PTGI) (Tedeschi & Calhoun, 1996; Spanish validation by Costa-Requena and Gil, 2007). It is a 21-item instrument based on a 6-point Likert scale (0=no change - 5=very high degree of change), which assesses positive changes experienced after a trauma. Total scores range from 0 to 105 with higher scores indicating better outcomes.

  4. Change in Therapeutic alliance (WAI-P) [ Time Frame: Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    Working Alliance Inventory-Patient Version (WAI-P; Horvath, 1981; Horvath & Greenberg, 1986, 1989; Spanish validation by Andrade-González & Fernández-Liria, 2015). It consists of 36 items with seven possible response options (1 = never, 2 = rarely, 3 = occasionally, 4 = sometimes, 5 = often, 6 = very often, 7 = always). The scoring range of the overall WAI-P is 36-252 points with higher scores indicating better outcomes.

  5. Change in Quality of Life (EQ-5D-3L) [ Time Frame: Time 1: Baseline; Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    EuroQoL-EQ-5D-3L (EuroQol Group, 1990; Spanish validation by Abadia et al., 1999). It consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Total scores range from 0-100 with higher scores indicating better outcomes.


Secondary Outcome Measures :
  1. Healthcare utilization [ Time Frame: Time 4: 12 months post-intervention ]
    Total number of visits to each healthcare professional (oncologist, nursing staff, psychologist, psychiatrist, social worker, emergency department) (Electronic Health Record).

  2. Change in Medication use and adherence (ARMS) [ Time Frame: Time 1: Baseline; Time 2: Change between Time 1 and 3 months post-intervention; Time 3: Change between Time 1 and 6 months post-intervention; Time 4: Change between Time 1 and 12 months post-intervention ]
    Adherence to Refills and Medications Scale (ARMS; Kripalani, Risser, Gatti, & Jacobson, 2009; Spanish validation by Gonzalez-Bueno et al., 2017). It consists of 12 questions: 8 aimed at assessing the patient's ability to properly administer the medication and 4 regarding its correct intake based on a four-point Likert scale (range from 1=never to 4=always; total score range 12-48), with lower scores indicating better adherence.

  3. Work absenteeism [ Time Frame: Time 4: 12 months post-intervention ]
    Number of days of patients' sick leaves (Electronic Health Record).

  4. Professionals' salaries [ Time Frame: Time 4: 12 months post-intervention ]
    Number of professionals involved in the online treatment or usual care as well as the number of professionals' working hours per week and costs (Electronic Health Record).

  5. Infrastructure costs [ Time Frame: Time 4: 12 months post-intervention ]
    Costs per user and per month for the development and maintenance of the online platform (experimental group) and costs of hospital's infrastructure per face-to-face visits per user and month.

  6. Transport costs [ Time Frame: Time 4: 12 months post-intervention ]
    Cost estimate per patient using a specific transport according to mobility data in Catalonia area.


Other Outcome Measures:
  1. Emotional wellbeing (experimental group only) [ Time Frame: Administration every 7 days until the end of treatment (or study completion), an average of 1 year ]
    Emotional thermometer (ET) - Visual Analogue Scale (VAS) (0-10) of the ICOnnecta't application.

  2. Health education [ Time Frame: Single administration per educational topic (7 thematic blocks, 16 topics, 40 questionnaires) until the end of treatment (or study completion), an average of 1 year ]
    Scores on health education questionnaires from Campus of ICOnnecta't. Higher scores indicate better health education acquisition.

  3. Usability (experimental group only) (SUS) [ Time Frame: 21 days after registration ]
    System Usability Scale (SUS) (Brooke, 1996). The SUS is a 10-item questionnaire with five response options that range from 4 = "Strongly agree" to 0 = "Strongly disagree". The SUS provides a "quick and dirty" reliable tool for measuring the usability of a range of systems.The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Higher scores indicate better outcomes.

  4. Satisfaction (experimental group only) [ Time Frame: 21 days after registration ]
    Visual Analogue Scale (VAS) (0-10).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged between 18 and 70 years with BC, within 6 weeks after diagnosis.
  • Having online access and a user-level knowledge of Internet.
  • Understanding of Spanish language.

Exclusion Criteria:

  • Major depressive episode.
  • Significant autolytic ideation.
  • Showing symptoms of psychosis or substance abuse.
  • Intellectual disability.
  • Having a mobile phone with an old release of Android operating system, which is not compatible with the platform.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04372459


Contacts
Layout table for location contacts
Contact: Cristian Ochoa, PhD +34 933357011 ext 3717 cochoa@iconcologia.cat
Contact: Dimitra Anastasiadou, PhD danastasiadou@idibell.cat

Sponsors and Collaborators
Institut Català d'Oncologia
Investigators
Layout table for investigator information
Principal Investigator: Cristian Ochoa, PhD Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Cristian Ochoa Arnedo, PhD, Clinical Psychologist, Institut Català d'Oncologia
ClinicalTrials.gov Identifier: NCT04372459    
Other Study ID Numbers: ICOnnectat-BC
PI19/01880 ( Other Grant/Funding Number: Instituto de Salud Carlos III )
First Posted: May 4, 2020    Key Record Dates
Last Update Posted: November 27, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The following IPD are to be shared with other researchers: Age (aggregated), civil status (aggregated), education (aggregated), occupational status (aggregated), date of enrolment (aggregated), date of opt out (aggregated and if applicable), date of oncological diagnosis (aggregated), cancer stage, oncological treatment (aggregated), psychotropic medication (aggregated), treatment arm in the study, and results from scales and subscales of psychometric instruments. Only ITT participants' data will be retained in the dataset.
Supporting Materials: Study Protocol
Time Frame: January 2023-January 2033
Access Criteria: Access will be granted through formal requests from interested researchers. In order to keep control on data access we will register contact details of these scientists and their objectives for data use.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cristian Ochoa Arnedo, Institut Català d'Oncologia:
e-health
breast cancer
survivors
psychosocial care
distress
Randomised Controlled Trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases